News | Dave Fornell

November 6, 2017 โ€” In the Hybrid REvascularization Versus Standards (HREVS) study that evaluated three different ...

Home November 06, 2017
Home
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab

November 6, 2017 โ€“ Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found no ...

Home November 06, 2017
Home
Technology | Advanced Visualization

November 6, 2017 โ€” TeraRecton announced the launch of version 4.4.13 of its iNtuition advanced visualization platform ...

Home November 06, 2017
Home
News | Heart Valve Technology

November 6, 2017 โ€” One year follow-up data from the SCOUT I Early Feasibility Study for the Mitralign Trialign System ...

Home November 06, 2017
Home
News | Antiplatelet and Anticoagulation Therapies

November 6, 2017 โ€” The first trial to evaluate the safety of dual antiplatelet therapy (DAPT) for less than 12 months in ...

Home November 06, 2017
Home
News | FFR Technologies

November 6, 2017 โ€” Three-year data from the FAME 2 study show patients with coronary artery disease who underwent a ...

Home November 06, 2017
Home
News | Stents Drug Eluting

November 6, 2017 โ€” Elderly patients undergoing percutaneous coronary intervention (PCI) often receive bare-metal stents ...

Home November 06, 2017
Home
News | Cardiac Imaging

November 6, 2017 โ€“ The Centers for Medicare & Medicaid Services (CMS) has finalized a New Technology Ambulatory Payment ...

Home November 06, 2017
Home
News | Stents Drug Eluting

November 3, 2017 โ€” Biotronik's Orsiro drug-eluting stent (DES) demonstrated high long-term safety and clinical ...

Home November 03, 2017
Home
News | Antiplatelet and Anticoagulation Therapies

November 3, 2017 โ€” A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests statins are ...

Home November 03, 2017
Home
The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was in October 2017.
Feature | Dave Fornell

November 3, 2017 โ€” Here is the list of the most popular articles and videos on the Diagnostic and Interventional ...

Home November 03, 2017
Home
News | Wearables

November 3, 2017 โ€” VitalConnect Inc. announced the fourth and final Series C closing, bringing the total Series C round ...

Home November 03, 2017
Home
Technology | FFR Technologies

Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist RXi Mini System, the next-generation system of its RXi Rapid Exchange FFR System. The RXi Mini System debuted at the 29th Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 2 in Denver.

Home November 03, 2017
Home
The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.
Feature | Atrial Fibrillation

November 2, 2017 โ€“ Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the ...

Home November 02, 2017
Home
The B. Braun Sequent Please drug-eluting balloon.
Feature | Drug-Eluting Balloons

November 2, 2017 โ€” The treatment of in-stent restenosis (ISR) remains challenging in clinical practice. The DARE (Drug ...

Home November 02, 2017
Home
Subscribe Now